Drug Trial Radar · NCT03575871
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
391
Actual
Start
Jun 29, 2018
Primary completion
Aug 13, 2019
Study completion Aug 13, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.
Conditions
- Dermatitis, Atopic
Interventions
PF-04965842 100 mgDrug
PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
PF-04965842 200 mgDrug
PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
PlaceboDrug
Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12Time frame: Baseline, Week 12
- Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12Time frame: Baseline, Week 12
Locations
115 sites in 13 countries. Site status is shown where the registry gives one.
Emmaus Research Center, Inc.
Anaheim, California
Advanced Research Center, Inc. - Los Alamitos Site
Los Alamitos, California
Peninsula Research Associates, Inc.
Rolling Hills Estates, California
Clinical Science Institute
Santa Monica, California
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
Colorado Springs Dermatology Clinic, PC
Colorado Springs, Colorado
Olympian Clinical Research
Clearwater, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Precision Imaging
Jacksonville, Florida
Solutions Through Advanced Research, Inc.
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
ForCare Clinical Research
Tampa, Florida
Imaging Center of Idaho
Caldwell, Idaho
ASR, LLC
Nampa, Idaho
Meridian Clinical Research
Baton Rouge, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
MediSearch Clinical Trials
Saint Joseph, Missouri
Sadick Research Group
New York, New York
PMG Research of Wilmington, LLC
Wilmington, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
The Ohio State University Dermatology East
Gahanna, Ohio
Tanenbaum Dermatology Center
Memphis, Tennessee
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee
Austin Institute for Clinical Research, Inc. - Central
Austin, Texas
Center for Clinical Studies, LTD. LLP
Houston, Texas
West Houston Dermatology, PA
Houston, Texas
Summit Clinical Research, LLC
Franklin, Virginia
Virginia Dermatology and Skin Cancer Center
Norfolk, Virginia
Australian Clinical Research Network
Maroubra, New South Wales, Australia
The Skin Centre
Benowa, Queensland, Australia
Veracity Clinical Research Pty Ltd
Woolloongabba, Queensland, Australia
Skin and Cancer Foundation Inc
Carlton, VIC 3053, Australia
Sinclair Dermatology
East Melbourne, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
The Royal Children's Hospital (RCH)
Parkville, Victoria, Australia
Medical Centre Asklepii OOD
Dupnitsa, Bulgaria
MHAT Dr. Tota Venkova AD
Gabrovo, Bulgaria
"Acibadem City Clinic MHAT Tokuda" EAD
Sofia, Bulgaria
"DCC Aleksandrovska" EOOD
Sofia, Bulgaria
Diagnostic Consultative Center Fokus-5
Sofia, Bulgaria
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.